A Phase 2 Study to Evaluate the Efficacy and Safety of BPN14770 in Participants with Mild Alzheimer's Disease
Phase 2
- Conditions
- mild Alzheimer's disease
- Registration Number
- JPRN-jRCT2031210149
- Lead Sponsor
- agata - Tsutae
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Participants who meet the criteria for probable AD dementia according to the Alzheimer's disease diagnostic criteria by National Institute on Aging-Alzheimer's Association (NIA-AA) and also meet the following criteria resulting in a clinical diagnosis of mild Alzheimer's disease.
1. CDR global score of 0.5 or 1 with a memory score of >= 0.5 at screening and prior to administration of study intervention.
2. MMSE score of 20 to 26 at screening.
Exclusion Criteria
Any medical or neurological condition (other than mild Alzheimer's disease) that might have been a contributing cause to the participant's cognitive impairment, including Lewy body dementia and frontotemporal dementia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method